Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy

Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy - Association of circulating tumor cell gene mutations and peripheral blood lymphocyte telomere length with the frequency and severity of immune-related pneumonitis in lung cancer patients receiving cancer immunotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046031

Enrollment

Registered

2021-12-01

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who has been histopathologically diagnosed with lung cancer. The patient who are planning to undergo cancer immunotherapy.

Exclusion criteria

Exclusion criteria: Those who do not consent to the research.

Design outcomes

Primary

Measure	Time frame
The frequency and severity of immune-related pneumonitis during cancer immunotherapy.	—

Countries

Japan

Contacts

Public ContactKohei Fujita

NHO Kyoto Medical Center Respiratory Medicine

kfujita.acd@gmail.com0756419161

Outcome results